Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents

• Egile Nagusiak: Valentina Cossiga (Egilea), Evelina La Civita (Egilea), Dario Bruzzese (Egilea), Maria Guarino (Egilea), Andrea Fiorentino (Egilea), Rosanna Sorrentino (Egilea), Giuseppina Pontillo (Egilea), Luca Vallefuoco (Egilea), Stefano Brusa (Egilea), Emma Montella (Egilea), Daniela Terracciano (Egilea), Filomena Morisco (Egilea), Giuseppe Portella (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: In more than 90% of chronic viral hepatitis C (HCV) patients treated with direct-acting antiviral agents (DAAs), a sustained viral response (SVR) was observed. Unfortunately, there are subgroups of subjects who display enduring liver fibrosis and are at high risk of developing hepatocell...